NCT04334044View on ClinicalTrials.gov

Treatment of SARS Caused by COVID-19 With Ruxolitinib

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

April 12, 2021

Study Completion Date

April 30, 2021

Conditions
COVID-19Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
DRUG

Ruxolitinib Oral Tablet

Ruxolitinib 5 mg twice a day

Trial Locations (1)

52763

Grupo Cooperativo de Hemopatías Malignas, Huixquilucan

All Listed Sponsors
lead

Grupo Cooperativo de Hemopatías Malignas

OTHER

NCT04334044 - Treatment of SARS Caused by COVID-19 With Ruxolitinib | Biotech Hunter | Biotech Hunter